<DOC>
	<DOC>NCT00435409</DOC>
	<brief_summary>The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.</brief_summary>
	<brief_title>A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Locally advanced or metastatic disease that can be measured. Patients with boneonly disease are also allowed to enter the study. Previous treatment with an anthracycline and a taxane in any setting Progression on first or second line regimen or adjuvant regimen if disease free interval less than 12 months History of inflammatory carcinoma if there is no other measurable disease More than 2 chemotherapy agents in the advanced disease setting Brain metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>